SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

Read more breaking news

 

 

UK herb player refutes echinacea allergy ruling

By Shane Starling , 09-Oct-2012
Last updated on 10-Oct-2012 at 11:14 GMT2012-10-10T11:14:23Z

UK herb player refutes echinacea allergy ruling

UK-based herbal supplements manufacturer A. Vogel says a recent medicines agency ruling that anti-cold and flu herb echinacea should not be sold to children under the age of 12 was based on outdated data.

The Medicines and Healthcare products Regulatory Agency (MHRA) made the ruling based on the potential for, “low risk of allergic reactions” even as it acknowledged that, This is not a serious safety issue…”.

Responding, A. Vogel said the ruling did not reflect the current understanding of echinacea.

Although we disagree with the MHRAs position, to remain within UK law, we have no choice but to comply and will change the dosage instructions on our packaging,” the company said.

“However, we felt that it was important for consumers to understand that, although the MHRA have made their announcement today, the advice they are giving is based on old data, rather than any new information on side effects received…”.

A. Vogel noted:

  • The monograph used to justify the MHRA decision was published in March 2008 and states that traditional use of echinacea for those under 12 years is not recommended. However, it also states that as a well-established use medicine, ‘specific risk in children over one year of age is not documented’ – in other words, there is no data on any specific risk when echinacea is used by children over the age of one.
  • The one research paper suggesting that in very rare circumstances echinacea can be associated with allergies, was published in 2002. It was an uncontrolled study and described 5 cases of adverse reactions in adults who were prone to conditions such as eczema, asthma and hayfever.
  • Since 2003, the company has received no reports of children under 12 experiencing allergic reactions to echinaforce (its echinacea product).

“The measures being taken are precautionary in nature. Parents should not worry if they have given echinacea to children unde r 12 in the past. Anyone who has concerns should speak to their doctor, pharmacist or qualified healthcare practitioner,” the MHRA said when it issued its warning in late August. 

The warning means the agency has to update two products that had been registered under the EU Traditional Herbal Medicinal Products Directive (THMPD) - Echinaforce Junior Cold & Flu Tablets and Echinaforce Chewable Cold & Flu Tablets.

A. Vogel agreed to over-label Echinaforce Tablets and Echinaforce Echinacea Drops to compy with the MHRA.

The agency also warned of an, “unknown number of unlicensed echinacea products on sale in the UK.”

The MHRA said it had followed the advice of the European Herbal Medicinal Products Committee (HMPC) and from the UK Herbal Medicines Advisory Committee (HMAC) in issuing the warning.

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars